Navigation Links
Decision Diagnostic Corp. (Formerly InstaCare) Announces 10% Stock Dividend
Date:12/6/2011

LOS ANGELES, Dec. 6, 2011 /PRNewswire/ -- Decision Diagnostics Corp., formerly known as InstaCare Corp. (OTCQB: ISCRD), a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the Board of Directors has approved the payment of a 10 percent stock dividend to all shareholders of record as of December 20, 2011. The dividend will be payable to shareholders of record no later than December 31, 2011.

Decision Diagnostics also announced that management is in the process of evaluating potential acquisitions to bolster the company's competitive position. The Board is committed to streamlining and simplifying the company's capital structure for the benefit of shareholders and to help improve the company's M&A capabilities. Accordingly, the Board has decided to reduce the authorized share count from 1.75 billion to approximately 495 million (494,995,000).  

Mr. Berman, CFO and Secretary commented, "We are moving earnestly to complete the strategic initiatives necessary to position Decision Diagnostics Corp. for a national listing on a major exchange. This proposed national listing, and our improved capital structure, are appropriate for a company of our size with the growth dynamics we have before us. Our position as a full-service provider of a wide and growing range of at-home diagnostics, poised to become a major player in the $20 billion worldwide market for at-home testing of blood glucose. A national listing will significantly enhance the visibility of our stock and improve liquidity, both to the long-term benefit of our loyal shareholders. In addition, the Board of Directors wanted to reward our shareholders with a one-time 10% stock dividend, and we are excited to announce that today."

Mr. Berman concluded, "We are in advanced discussions with potential targets and hope to have M&A-related announcements in the coming days.  We are redoubling our efforts to close these potential M&A activities before the end of the year. Our actions follow the previously announced 1 for 14 reverse split, effective December 1, 2011. These changes the company's capital structure are part of an effort to qualify to have our common stock to be listed on a national exchange, with the goal of applying to the NASDAQ Bx exchange early in 2012."

For more information about Decision Diagnostics Corp., Pharma Tech Solutions, Inc. and/or its revolutionary MD@Hand cell phone centric technologies, please visit the Decision Diagnostics Corp. web site www.decisiondiagnostics.com or www.pharmatechdirect.com, or call the company at (805) 446-2973.

Forward-Looking Statements

This news release contains forward-looking statements about our business, or financial condition and prospects that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.


'/>"/>
SOURCE Decision Diagnostics Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Commissioner announces Avastin decision
2. Sanofi Pasteur Launches Nationwide Education Campaign to Help Parents Make Informed Decisions about Immunization
3. Pharmaceutical Executives Use New Search Function for Data-Informed Decision-Making
4. e-Zassi and UBM Canon Partner to Provide Online Medical Device Decision Support Tools at Qmed.com
5. American College of Medical Genetics Applauds HHS Secretarys Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease
6. Experis Recognizes National Healthcare IT Week, Provides Tips for ICD-10 Assessment Decision
7. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
8. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
9. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
10. ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions
11. ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is ... from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... body recognizes its raw form (unlike the synthetically made options that are on the ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
Breaking Medicine News(10 mins):